Separately, in their guidance, NICE had recommended avelumab as an option for treating metastatic Merkel cell carcinoma in adults, only if they have had 1 or more lines of chemotherapy for metastatic disease.
Avelumab was also recommended for use within the Cancer Drugs Fund as an option for treating metastatic Merkel cell carcinoma in adults, if they have not had chemotherapy for metastatic disease and the conditions in the managed access agreement for avelumab are followed.